Reduced expression of BMP3 contributes to the development of pulmonary fibrosis and predicts the unfavorable prognosis in IIP patients
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1495 views | HTML 3136 views | ?
Xiaoting Yu1,*, Pan Gu1,*, Ziling Huang1,*, Xia Fang2, Ying Jiang3, Qun Luo3, Xia Li4, Xuyou Zhu1, Mengna Zhan5, Junbang Wang6, Lichao Fan7, Rongchang Chen3, Juehua Yu6, Yingying Gu3, Aibin Liang2 and Xianghua Yi1
1Department of Pathology, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China
2Department of Biotherapy, Tongji Hosptial, Tongji University School of Medicine, Shanghai 200065, China
3The State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Disease, the First Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong 510120, China
4Department of Respiratory, Shanghai Pulmonary Hospital, Tongji Universiy School of Medicine, Shanghai 200433, China
5Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai 200032, China
6Stem Cell Translational Research Center, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China
7Department of Respiratory, Tongji Hospital, Tongji University School of Medicine, Shanghai 200065, China
*These authors contributed equally to this work
Xianghua Yi, email: [email protected]
Aibin Liang, email: [email protected]
Yingying Gu, email: [email protected]
Keywords: bone morphogenetic protein 3/BMP3, transforming growth factor-β/TGF-β, idiopathic pulmonary fibrosis/IPF, idiopathic nonspecific interstitial pneumonia/INSIP
Received: June 03, 2017 Accepted: July 25, 2017 Published: August 09, 2017
Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (INSIP) are two related diseases involving varying degrees of pulmonary fibrosis with no effective cure. Bone morphogenetic protein 3 (BMP3) is a member of the transforming growth factor-β (TGF-β) super-family, which has not been implicated in pulmonary fibrosis previously. In this study, we aimed to investigate the potential role of BMP3 playing in pulmonary fibrosis from clinical diagnosis to molecular signaling regulation. RNA sequencing was performed to explore the potential biomarker of IIP patients. The expression of BMP3 was evaluated in 83 cases of IPF and INSIP by immunohistochemistry. The function of BMP3 was investigated in both fibroblast cells and a bleomycin-induced murine pulmonary fibrosis model. The clinical relevance of BMP3 expression were analyzed in 47 IIP patients, which were included in 83 cases and possess more than five-year follow-up data. Both RNA-sequencing and immunohistochemistry staining revealed that BMP3 was significantly down-regulated in lung tissues of patients with IPF and INSIP. Consistently, lower expression of BMP3 also was found in pulmonary fibrotic tissues of bleomycin-induced mice model. Up-regulation of BMP3 prevented pulmonary fibrosis processing through inhibiting cellular proliferation of fibroblasts as well as TGF-β1 signal transduction. Finally, the relatively higher expression of BMP3 in IPF patients was associated with less/worse mortality. Intravenous injection of recombinant BMP3. Taken together, our results suggested that the low expression level of BMP3 may indicate the unfavorable prognosis of IPF patients, targeting BMP3 may represent a novel potential therapeutic method for pulmonary fibrosis management.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.